Get the Stockscreener App
207.40
0.37%
0.7962
Overview
News
Price History
Option Chain
Financials
Why ABBV Down?
Discussions
Forecast
Dividend History
Abbvie Inc stock is traded at $207.40, with a volume of 2.05M.
It is up +0.37% in the last 24 hours and down -0.71% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
See More
Previous Close:
$206.60
Open:
$205.71
24h Volume:
2.05M
Relative Volume:
0.29
Market Cap:
$366.68B
Revenue:
$62.82B
Net Income/Loss:
$3.62B
P/E Ratio:
102.01
EPS:
2.0331
Net Cash Flow:
$17.82B
1W Performance:
+5.06%
1M Performance:
-0.71%
6M Performance:
-3.95%
1Y Performance:
+4.48%
1-Day Range:
$204.87
$208.15
1-Week Range:
$190.75
$214.87
52-Week Range:
$176.57
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV vs LLY, JNJ, AZN, MRK
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
207.31 | 365.43B | 62.82B | 3.62B | 17.82B | 2.0331 |
LLY
Lilly Eli Co
|
963.97 | 862.01B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
225.06 | 546.90B | 96.36B | 21.04B | 17.80B | 8.6488 |
AZN
Astrazeneca Plc
|
183.71 | 286.50B | 60.48B | 10.40B | 8.05B | 3.3297 |
MRK
Merck Co Inc
|
113.62 | 277.02B | 65.59B | 8.93B | 12.36B | 3.5532 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Initiated | Canaccord Genuity | Buy |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-08-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-10-25 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-04-25 | Downgrade | DZ Bank | Buy → Hold |
| Oct-14-25 | Downgrade | Erste Group | Buy → Hold |
| Oct-01-25 | Downgrade | HSBC Securities | Buy → Hold |
| Sep-17-25 | Upgrade | Berenberg | Hold → Buy |
| Aug-12-25 | Resumed | Piper Sandler | Overweight |
| Aug-07-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-05-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
5,538 Shares in AbbVie Inc. $ABBV Acquired by Legacy Edge Advisors LLC - MarketBeat
Kornitzer Capital Management Inc. KS Acquires 5,020 Shares of AbbVie Inc. $ABBV - MarketBeat
Heritage Wealth Management, Inc.'s AbbVie Inc(ABBV) Holding History - GuruFocus
AbbVie (ABBV) Reports Q1 Revenue Growth Despite Earnings Miss - GuruFocus
AB Sustainable Thematic Balanced Portfolio's AbbVie Inc(ABBV) Holding History - GuruFocus
The Most Important Part of These 3 Big Pharma Earnings Reports Wasn’t the Beat - MarketBeat
Strs Ohio Has $181.81 Million Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. Just Missed EarningsBut Analysts Have Updated Their Models - Yahoo Finance
PFA Pension Forsikringsaktieselskab Buys New Shares in AbbVie Inc. $ABBV - MarketBeat
Robertson Stephens Wealth Management LLC Acquires 34,246 Shares of AbbVie Inc. $ABBV - MarketBeat
Horizon Investments LLC Has $31.65 Million Holdings in AbbVie Inc. $ABBV - MarketBeat
AbbVie (NYSE:ABBV) Upgraded to Strong-Buy at DZ Bank - MarketBeat
OMC Financial Services LTD's AbbVie Inc(ABBV) Holding History - GuruFocus
Benjamin Edwards Inc. Has $77.83 Million Stock Position in AbbVie Inc. $ABBV - MarketBeat
Artemis Investment Management LLP Has $160.86 Million Stock Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. (NYSE:ABBV) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
AbbVie (NYSE:ABBV) Updates Q2 2026 Earnings Guidance - MarketBeat
AbbVie (NYSE:ABBV) Stock Price Down 2.2%Here's What Happened - MarketBeat
Thrivent Moderately Aggressive Allocation Fund's AbbVie Inc(ABBV) Holding History - GuruFocus
AbbVie Inc. stock underperforms Friday when compared to competitors - MarketWatch
AbbVie’s Earnings Beat Wall Street’s Estimates. Investors Are Still Worried - WSJ
ABBV Reiterated by Guggenheim -- Price Target Maintained at $249 - GuruFocus
10 Health Care Stocks With Whale Alerts In Today's SessionAbbVie (NYSE:ABBV), AtaiBeckley (NASDAQ:ATAI - Benzinga
U.S. Large Cap Growth Portfolio's AbbVie Inc(ABBV) Holding History - GuruFocus
AbbVie (NYSE: ABBV) Posts Q1 Revenue of $15B, Raises Guidance - Value The Markets
AbbVie Stock Beats Q1 Estimates as Skyrizi Hits $4.5B in a Single Quarter - TIKR.com
AbbVie option and FDA feedback reshape Aldeyra (Nasdaq: ALDX) drug plans - Stock Titan
Netflix, Cisco, Zoom And A Health Care Stock On CNBC's 'Final Trades'Cisco Systems (NASDAQ:CSCO) - Benzinga
SNS Financial Group LLC Has $2.97 Million Stake in AbbVie Inc. $ABBV - MarketBeat
Oppenheimer & Co. Inc. Sells 8,094 Shares of AbbVie Inc. $ABBV - MarketBeat
Fifth Third Bancorp Grows Stock Holdings in AbbVie Inc. $ABBV - MarketBeat
Danske Bank A S Has $267.24 Million Stock Holdings in AbbVie Inc. $ABBV - MarketBeat
Is AbbVie Inc. (ABBV) One of the Best Drug Stocks to Buy According to Analysts? - Yahoo Finance
Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2026 - GlobeNewswire Inc.
U.S. Growth Trust's AbbVie Inc(ABBV) Holding History - GuruFocus
FDA filing for investigational alopecia areata treatment lifts AbbVie stock 3.65% - Traders Union
AbbVie stock jumps 3.65% as Q1 2026 earnings call announcement boosts sentiment - Traders Union
Bank of America Upgrades AbbVie (ABBV) on Skyrizi Strength, Lifts PT - Insider Monkey
AbbVie Inc (ABBV) Stock Up 3.6% but GF Value Says Overvalued -- GF Score: 86/100 - GuruFocus
AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec - Investing News Network
AbbVie Inc. stock outperforms competitors on strong trading day - MarketWatch
AbbVie: Balancing Potential Acquisition Impact With Positive Q1 2026 Earnings (NYSE:ABBV) - Seeking Alpha
AbbVie and adMare BioInnovations Award RIME Therapeutics to Advance Biotech Innovation in Quebec - Quiver Quantitative
ABBV Maintained by Morgan Stanley -- Price Target Raised to $278 - GuruFocus
Federated Hermes MDT Market Neutral ETF's AbbVie Inc(ABBV) Holding History - GuruFocus
AbbVie Q1 earnings loom: Buy or sell the stock ahead of results? - MSN
AbbVie Expected to Post Durable Growth Into Mid-2030s, BofA Securities Says - marketscreener.com
New York State Teachers Retirement System Sells 39,154 Shares of AbbVie Inc. $ABBV - MarketBeat
ABBV Reiterates by Cantor Fitzgerald -- Price Target Maintained at $240 - GuruFocus
Price Prediction: Why AbbVie’s Post-Humira Pivot Makes It a Strong Buy - Yahoo Finance
AbbVie Stock Forecast: Trending Buy Calls From Analysts - TipRanks
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.68%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):